PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat brain cancer
Disease control CompletedThis study tested a combination of three drugs (ibrutinib, rituximab, and lenalidomide) in 25 adults with recurrent or treatment-resistant central nervous system lymphoma. The main goal was to find the safest dose of ibrutinib when given with the other two drugs. Researchers also…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 07:38 UTC
-
Can a cancer drug stop brain lymphoma from returning?
Disease control CompletedThis study tested whether the drug nivolumab can safely prevent primary central nervous system lymphoma (PCNSL) from returning in people who still had signs of tumor DNA in their spinal fluid after finishing their first chemotherapy. Fourteen participants received nivolumab as a …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC